Pricing Log in Create free account

Aprea Therapeutics, Inc. (APRE) vs Exicure, Inc. (XCUR)

Aprea Therapeutics, Inc. and Exicure, Inc. are both Biotechnology companies. Aprea Therapeutics, Inc. and Exicure, Inc. are of similar size ($6.2M and $5.8M). Exicure, Inc. grew revenue faster over the last twelve months: 2,366.5% against −81.0%. Across the 12 metrics below, Aprea Therapeutics, Inc. leads on 8 and Exicure, Inc. on 4.

Valuation

Metric APRE XCUR Biotechnology median
P/E n/m n/m 10.60
P/S 97.70 0.22 9.40
P/B 0.82 5.94 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.65 n/m 0.66
EV/Sales (34.76) 0.19 9.02
Earnings yield (134.54%) (145.05%) (32.88%)
Free cash flow yield (45.64%) (102.61%) (23.13%)

Profitability

Metric APRE XCUR Biotechnology median
Gross margin 100.00% 80.08% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (62.83%) (168.37%) (51.96%)
Return on assets (53.24%) (54.98%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APRE XCUR Biotechnology median
Revenue growth (TTM) (80.99%) 2,366.45% 6.76%
EPS growth (last fiscal year) 17.87% 83.37% 29.88%
Revenue growth, 5-year CAGR — 33.48% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APRE XCUR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 9.67 0.56 4.97
Net debt to EBITDA 1.11 0.99 1.01

Dividend

Metric APRE XCUR Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric APRE XCUR Biotechnology median
Market cap 6.24m 5.83m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack